ResMed Inc.
ResMed
ResMed is the world's leading digital health technology company specializing in sleep apnea and respiratory care devices, founded in 1989 in San Diego, California, USA. With annual revenue of $5.1 billion, the company operates 8+ factories across 6 countries, employing over 10,000 people. ResMed's CPAP and BiPAP devices, combined with its myAir cloud platform, create a powerful ecosystem that sets the global standard for home respiratory care.
Strengths: Dominant 59.4% gross margin through device+software subscription model; myAir platform has millions of active daily users; strong IP portfolio with continuous innovation in digital sleep therapy; highly profitable with 28% operating profit growth in FY2025.
Weaknesses: Heavy reliance on sleep apnea market (single-disease risk); faces potential competition from weight-loss drugs like GLP-1 agonists; Phillip's re-entry into the market could disrupt market share.Read MoreShow Less
Strengths: Dominant 59.4% gross margin through device+software subscription model; myAir platform has millions of active daily users; strong IP portfolio with continuous innovation in digital sleep therapy; highly profitable with 28% operating profit growth in FY2025.
Weaknesses: Heavy reliance on sleep apnea market (single-disease risk); faces potential competition from weight-loss drugs like GLP-1 agonists; Phillip's re-entry into the market could disrupt market share.
Listed market data
RMD · NYSE · weeklyHistory →- Market cap
- $33.6 B
- Share price
- USD 238.97
- 1Y change
- -10.9%
- Recent change
- -0.1%
- Since first close
- ×337
- Revenue (TTM)
- $5.7 B
10-22 → 10-23
from 1995-06
Financial history
Full market history- 2026-10USD 238.97$33.6 B+8.1%
- 2026-09USD 221.10$29.4 B-7.9%
- 2026-08USD 240.10$31.9 B+13.8%
- 2026-07USD 210.98$28 B+8.3%
- 2026-06USD 194.88$25.9 B+2.3%
- 2026-05USD 190.57$25.3 B-10.9%
- 2026-04USD 213.81$28.4 B-4.8%
- 2026-03USD 224.48$29.8 B-12.4%
- 2026-02USD 256.26$34.1 B-0.8%
- 2026-01USD 258.31$34.3 B+7.2%
- 2025-12USD 240.87$32 B-5.8%
- 2025-11USD 255.83$34 B—
In the press
All coverage →5 latest headlines- New Mask Launch Could Be A Big Test For ResMed Stock - Simply Wall Streetsimplywall.st2026-10-20
- ETFs Are Net Sellers of ResMed (RMD) on Oct. 16 - Yahoo Financefinance.yahoo.com2026-10-20
- Resmed Launches Fabric Full Face Mask in the United States - Sleep Reviewsleepreviewmag.com2026-10-19
- Resmed Introduces Full Face Fabric CPAP Mask - Respiratory Therapyrespiratory-therapy.com2026-10-19
- Resmed to launch AirTouch F40 full-face fabric CPAP mask in US - MassDevicewww.massdevice.com2026-10-19
• Flow generators, CPAP and BiPAP devices for obstructive sleep apnea treatment
• Masks, headgear, and consumable accessories with high recurring replacement demand
• myAir digital health platform for remote patient monitoring and compliance data
• Ventilators for home and hospital use across multiple respiratory conditions
• Cloud-connected sleep therapy management software suite
• Nasal and full-face mask portfolio with advanced seal technologies
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2026 | $5.7 B | $1.5 B |
| 2025 | $5.1 B | $1.4 B |
| 2024 | $4.7 B | $1 B |
| 2023 | $4.2 B | $898 M |
| 2022 | $3.6 B | $779 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
La Jolla, California, United States
Founded
1989
Employees
10000+
Revenue
$5.1 B
Market cap
$33.6 B
Factories
8+ factories in 6 countries
Presence
140+ Countries
Listing
NYSE: RMD
Categories
Related
Similar listed companies
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- F. Hoffmann-La Roche AG· $372 B
- General Electric Company (GE)· $326 B
- Thermo Fisher Scientific Inc.· $255 B
- Abbott Laboratories· $183 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NYSE: RMD , Data Sources & Methodology
ResMed Official Website
ResMed FY2025 Results
ResMed - Wikipedia
ResMed Indiana Distribution Center